Suchergebnisse
Filter
14 Ergebnisse
Sortierung:
Data now
In: Index on censorship, Band 41, Heft 1, S. 178-179
ISSN: 1746-6067
Narco Tales
In: Index on censorship, Band 40, Heft 1, S. 146-149
ISSN: 1746-6067
Bloggers and citizen journalists are telling the stories that the mainstream Mexican media no longer dares to report, says Ana Arana
How the Street Gangs Took Central America
In: Foreign affairs: an American quarterly review, Band 84, Heft 3, S. 98
ISSN: 2327-7793
How the street gangs took Central America
In: Foreign affairs, Band 84, Heft 3, S. 98-110
ISSN: 0015-7120
World Affairs Online
Essays - How the Street Gangs Took Central America
In: Foreign affairs, Band 84, Heft 3, S. 98-110
ISSN: 0015-7120
La nueva batalla de Centroamerica
In: Foreign affairs en español, Band 2, Heft 1, S. 222-232
ISSN: 1665-1707
World Affairs Online
Essays - The New Battle for Central America - In the years since its civil wars ended, this blood-soaked region has been forgotten by the international community. Now Central America risks sliding into a new kind of anarchy, thanks to the legacy of flawed peace treaties, international inattention, r...
In: Foreign affairs, Band 80, Heft 6, S. 88-101
ISSN: 0015-7120
The new battle for Central America
In: Foreign affairs, Band 80, Heft 6, S. 88-101
ISSN: 0015-7120
World Affairs Online
The New Battle for Central America
In: Foreign affairs: an American quarterly review, Band 80, Heft 6, S. 88
ISSN: 2327-7793
The Smiling Chameleon
In: Bulletin of the atomic scientists, Band 50, Heft 6, S. 36-39
ISSN: 1938-3282
The smiling chameleon
In: The bulletin of the atomic scientists: a magazine of science and public affairs, Band 50, Heft 6, S. 36-39
ISSN: 0096-3402, 0096-5243, 0742-3829
World Affairs Online
Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening
BELE Study Group leaded by Xavier Castells are listed here in alphabetical order and grouped by institution: (a) IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain: Andrea Burón, Xavier Castells, Merce Comas, Jose Maria Corominas, Javier Louro, Ana Rodríguez-Arana, Marta Román, Maria Sala, Sonia Servitja, Mar Vernet-Tomas; (b) Corporació Sanitària Parc Taulí, Sabadell, Spain: Marisa Baré, Nuria Tora; (c) Catalan Institute of Oncology, Barcelona, Spain: Llucia Benito, Carmen Vidal (d) Hospital Santa Caterina, Girona, Spain: Joana Ferrer; (e) Catalan Institute of Oncology, Girona, Spain: Rafael Marcos-Gragera; (f) Hospital de la Santa Creu i Sant Pau, Barcelona, Spain: Judit Solà-Roca, María Jesús Quintana; (g) General Directorate of Public Health, Government of Cantabria, Spain: Mar Sánchez; (h) Principality of Astúrias Health Service, Spain: Miguel Prieto; (i) Fundació Lliga per a La Investigació i Prevenció Del Cáncer, Tarragona, Spain: Francina Saladié, Jaume Galceran; (j) Hospital Clinic, Barcelona, Spain; Xavier Bargalló, Isabel Torá-Rocamora; (k) Vallés Oriental Breast Cancer Early Detection Program, Spain; Lupe Peñalva; (l) Catalonian Cancer Strategy, Barcelona, Spain: Josep Alfons Espinàs. ; IRIS Study Group leaded by Marta Román are listed here in alphabetical order and grouped by institution: (a) IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain: Rodrigo Alcantara, Xavier Castells, Laia Domingo, Javier Louro, Margarita Posso, Maria Sala, Ignasi Tusquets, Ivonne Vazquez, Mar Vernet-Tomas; (b) Corporació Sanitària Parc Taulí, Sabadell, Spain: Marisa Baré, Javier del Riego; (c) Catalan Institute of Oncology, Barcelona, Spain: Llucia Benito, Carmen Vidal (d) Hospital Santa Caterina, Girona, Spain: Joana Ferrer; (e) Catalan Institute of Oncology, Girona, Spain: Rafael Marcos-Gragera; (f) Hospital de la Santa Creu i Sant Pau, Barcelona, Spain: Judit Solà-Roca, María Jesús Quintana; (g) General Directorate of Public Health, Government of Cantabria, Spain: Mar Sánchez; (h) ...
BASE
Hormonal dependence and cancer in Systemic Lupus Erythematosus
Objective: To estimate the incidence and analyze any cancer-associated factors in patients with systemic lupus erythematosus (SLE), differentiating between hormone-sensitive (HS) and non-HS cancers. Methods: This was a retrospective multicenter study of a patient cohort from the Systemic Lupus Erythematosus Registry of the Spanish Society of Rheumatology. Included were the first cancer post-SLE diagnosis, clinical and sociodemographic information, cumulative damage, severity, comorbidities, treatments, and refractoriness. Cancers were classified as HS (prostate, breast, endometrium, and ovarian) and non-HS (the remainder). The standardized incidence ratio (SIR) was calculated and logistic regression models were built. Results: A total of 3,539 patients (90.4% women) were included, 154 of whom had cancer (91% female), and 44 had HS cancer (100% female). The cancer SIR was 1.37 (95% confidence interval [95% CI] 1.15-1.59), with higher values in women age <65 years (SIR 2.38 [95% CI 1.84-2.91]). The SIR in women with HS versus non-HS cancer was 1.02 (95% CI 0.13-1.91) and 1.93 (95% CI 0.98-2.89). In HS versus non-HS cancers, SLE diagnostic age (odds ratio [OR] 1.04 [P = 0.002] versus 1.04 [P = 0.019]), and period of disease evolution (OR 1.01 [P < 0.001] versus 1.00 [P = 0.029]) were associated with cancer. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (OR 1.27 [P = 0.022]) and angiotensin-converting enzyme (ACE) inhibitor prescriptions (OR 2.87 [P = 0.048]) were associated with non-HS cancers. Conclusion: Cancer incidence in patients with SLE was higher than in the Spanish population, particularly among young women. This increase might be due to non-HS cancers, which would be associated with SLE involving greater cumulative damage where more ACE inhibitors are prescribed. ; The RELESSER Registry was partially funded by GSK, Roche, UCB, Lilly and Novartis. The sponsors had no role in the study design, data collection, analysis or interpretation, in writing the report, or in the decision to submit the article for publication. Dr. Pego-Reigosa is supported by grant 316265 (BIOCAPS) from the European Union 7th Framework Program (FP7/REGPOT-2012- 2013.1). The FIS Grant PI11/02857 (Instituto Carlos III, Fondos FEDER) supported this study.
BASE